Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- yes (3)
Document Type
- Journal article (2)
- Doctoral Thesis (1)
Keywords
- brain (3) (remove)
Institute
- Institut für Anatomie und Zellbiologie (3) (remove)
Protocadherins (PCDHs) belong to the cadherin superfamily and represent the largest subgroup of calcium-dependent adhesion molecules. In the genome, most PCDHs are arranged in three clusters, α, β, and γ on chromosome 5q31. PCDHs are highly expressed in the central nervous system (CNS). Several PCDHs have tumor suppressor functions, but their individual role in primary brain tumors has not yet been elucidated. Here, we examined the mRNA expression of PCDHGC3, a member of the PCDHγ cluster, in non-cancerous brain tissue and in gliomas of different World Health Organization (WHO) grades and correlated it with the clinical data of the patients. We generated a PCDHGC3 knockout U343 cell line and examined its growth rate and migration in a wound healing assay. We showed that PCDHGC3 mRNA and protein were significantly overexpressed in glioma tissue compared to a non-cancerous brain specimen. This could be confirmed in glioma cell lines. High PCDHGC3 mRNA expression correlated with longer progression-free survival (PFS) in glioma patients. PCDHGC3 knockout in U343 resulted in a slower growth rate but a significantly faster migration rate in the wound healing assay and decreased the expression of several genes involved in WNT signaling. PCDHGC3 expression should therefore be further investigated as a PFS-marker in gliomas. However, more studies are needed to elucidate the molecular mechanisms underlying the PCDHGC3 effects.
Energy demand of neurons in brain that is covered by glucose supply from the blood is ensured by glucose transporters incapillaries and brain cells. In brain, the facilitative diffusion glucose transporters GLUT1-6 and GLUT8, and the Na+-D-glucosecotransporters SGLT1 are expressed. The glucose transporters mediate uptake of D-glucose across the blood-brain barrier anddelivery of D-glucose to astrocytes and neurons. They are critically involved in regulatory adaptations to varying energy demandsin response to differing neuronal activities and glucose supply. In this review, a comprehensive overview about verified andproposed roles of cerebral glucose transporters during health and diseases is presented. Our current knowledge is mainly based onexperiments performed in rodents. First, the functional properties of human glucose transporters expressed in brain and theircerebral locations are described. Thereafter, proposed physiological functions of GLUT1, GLUT2, GLUT3, GLUT4, andSGLT1 for energy supply to neurons, glucose sensing, central regulation of glucohomeostasis, and feeding behavior are compiled, and their roles in learning and memory formation are discussed. In addition, diseases are described in which functionalchanges of cerebral glucose transporters are relevant. These are GLUT1 deficiency syndrome (GLUT1-SD), diabetes mellitus, Alzheimer’s disease (AD), stroke, and traumatic brain injury (TBI). GLUT1-SD is caused by defect mutations in GLUT1. Diabetes and AD are associated with changed expression of glucose transporters in brain, and transporter-related energy defi-ciency of neurons may contribute to pathogenesis of AD. Stroke and TBI are associated with changes of glucose transporter expression that influence clinical outcome
Glukose ist einer der Hauptenergielieferanten der Säugetierzellen. Aus diesem Grund wird die Glukoseaufnahme durch erleichterte Diffusion durch die GLUT (SLC2) Familie, sowie durch die Familie der sekundär aktiven Transporter SGLT (SLC5A) gesichert. In dieser Arbeit wurde ein polyklonaler Antikörper gegen SGLT1 aus Kaninchen hergestellt. Dieser Antikörper wurde für die Innunhistologie sowie für Western blots eingesetzt. Man sah eine Anfärbung von Bürstensaummembranen an Dünndarm- und Nierentubulusepithelzellen, aber in diesen Geweben nicht an Mikrogefäßen. Darüberhinaus konnten wir SGLT1 an der basolateralen Membran von Speicheldrüsenazini sehen, auch hier konnten wir SGLT1 in den Kapillaren nicht sehen. Überraschenderweise konnte SGLT1 in der Blut-Hirn-Schranke nachgewiesen werden. Auch konnte man die Lokalisation von SGLT1 in den Kapillaren des Herzens und des Skelettmuskels zeigen. Die physiologische und pathophysiologische Bedeutung dieser Lokalisationen liegt noch im Unklaren.